Going-concern and financing shortfall
The company expects to need additional capital to fund operations and complete CLS-AX development.
- Scope
- Cash burn, dilution, debt covenants or forced restructuring
- Materiality
- high
Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies delivered into the suprachoroidal space of the eye. Its commercial product, XIPERE, is licensed to partners in the U.S., Canada and parts of Asia-Pacific, while the company’s internal development efforts are centered on CLS-AX and other eye-disease candidates using its SCS Microinjector platform.
−1 722,1 %
91,0 %
−2 064,4 %
−79,8 %
4.44
4.44
| % | |
|---|---|
| Commercial ophthalmic product | 20% XIPERE is the company’s approved therapy delivered into the suprachoroidal space for eye disease. |
| Drug delivery platform | 25% The SCS Microinjector platform enables targeted suprachoroidal administration of ophthalmic therapies. |
| License and collaboration revenue | 45% Upfront, milestone and royalty-based payments from partners using the platform or product rights. |
| Development pipeline | 10% CLS-AX and other proprietary ophthalmic candidates under preclinical and clinical development. |
Clearside sells primarily to pharmaceutical and ophthalmology partners rather than to end patients directly...
- Commercial licenseesprimary
Partners such as Bausch + Lomb and Arctic Vision that commercialize XIPERE in licensed territories.
- Development collaboratorsprimary
Pharma and biotech companies that pay for access to the SCS Microinjector and related know-how.
- Approved-product distributorssecondary
Licensees that buy SCS Microinjector kits for use with approved ophthalmic products.
- Future pipeline partnersemerging
Potential partners for CLS-AX and other candidates if Clearside chooses to out-license development or commercialization.
Clearside is headquartered in the United States and its commercial footprint is shaped by partner territories rather...
- •United States is the operating and financing center
- •Canada is a licensed commercialization market for XIPERE
- •Asia-Pacific, excluding Japan, is licensed to Arctic Vision
- •Health Canada approval expands the Canadian market opportunity
- •Geography is partner-driven, not direct-sales driven
Clearside’s near-term strategy is to preserve cash while advancing CLS-AX and other proprietary ophthalmic candidates...
01
Complete CLS-AX developmentshort-term
The company needs a successful late-stage asset to create future product revenue and reduce dependence on licensing income.
02
Expand platform partnershipsmedium-term
Additional collaborations can generate non-dilutive cash and validate the SCS Microinjector in more indications.
03
Secure financing and strategic flexibilityshort-term
The company has a limited cash runway and needs capital to continue development and avoid forced restructuring.
Clearside faces substantial going-concern and financing risk because it has recurring losses, negative operating cash...
Strategic alternative / liquidation risk
Management disclosed that failure to complete a strategic alternative could lead to bankruptcy, wind-down or dissolution.
- Scope
- Residual value for common shareholders
- Materiality
- high
Clinical and regulatory failure for CLS-AX
Pipeline value depends on successful development and approval of the lead candidate.
- Scope
- R&D spend and future product revenue
- Materiality
- high
Partner and licensing concentration
Revenue has historically come mainly from license agreements and collaboration payments.
- Scope
- XIPERE territories and future platform deals
- Materiality
- high
Nasdaq delisting risk
Non-compliance with listing requirements could reduce liquidity and investor access.
- Scope
- Trading price and marketability of shares
- Materiality
- medium
License and collaboration revenue recognition
Can create lumpy quarterly revenue and non-cash revenue recognition
Royalty financing obligation
Affects interest expense and carrying value of the financing liability
Warrant fair value accounting
Can cause non-operating income statement volatility
Clinical trial accruals and R&D estimates
Can move research expense and operating loss timing
: 28.4.2026